Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients

: This retrospective review compared oral valganciclovir (VGCV) 450 mg daily for 6 months versus oral ganciclovir (GCV) 1000 mg 3 times daily for 3 months in preventing cytomegalovirus (CMV) disease in high‐risk liver transplant recipients. We evaluated all CMV donor positive–recipient negative live...

Full description

Saved in:
Bibliographic Details
Published in:Transplant infectious disease 2009-04, Vol.11 (2), p.106-111
Main Authors: Brady, R.L., Green, K., Frei, C., Maxwell, P.
Format: Article
Language:English
Subjects:
Administration, Oral
Antiviral Agents - therapeutic use
Cytomegalovirus
Cytomegalovirus Infections - epidemiology
Cytomegalovirus Infections - prevention & control
Female
ganciclovir
Ganciclovir - administration & dosage
Ganciclovir - analogs & derivatives
Humans
Incidence
liver transplant
Liver Transplantation
Male
Middle Aged
Postoperative Complications - epidemiology
Postoperative Complications - prevention & control
Postoperative Complications - virology
prophylaxis
Retrospective Studies
Texas
Treatment Outcome
valganciclovir
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:: This retrospective review compared oral valganciclovir (VGCV) 450 mg daily for 6 months versus oral ganciclovir (GCV) 1000 mg 3 times daily for 3 months in preventing cytomegalovirus (CMV) disease in high‐risk liver transplant recipients. We evaluated all CMV donor positive–recipient negative liver transplant recipients managed at University Health System in San Antonio, Texas from August 1996 to September 2006. CMV disease was confirmed by polymerase chain‐reaction or antigenemia assay, and CMV invasive disease by tissue biopsy. Patient demographics, laboratory results, complications, and therapies were collected via retrospective chart review. Patients
ISSN:1398-2273
1399-3062
DOI:10.1111/j.1399-3062.2008.00356.x